Press Releases for MBRX

Press Releases
Ligand to Acquire Metabasis for Cash and Contingent Value Rights
Metabasis Therapeutics Receives Notice of Noncompliance With Nasdaq Listing Requirements
Metabasis Therapeutics Receives Notice of Delisting From Nasdaq Capital Market
Metabasis Therapeutics Announces Second Quarter 2009 Financial Results
Metabasis Announces Conference Call and Live Webcast to Discuss Second Quarter 2009 Financial Results
Metabasis Therapeutics Receives a Development Event Payment from Roche and Notification That Roche Plans to Advance MB11362 into Development for the Treatment of Hepatitis C
Metabasis Therapeutics Announces Corporate Restructuring and Notice of Noncompliance With Nasdaq Listing Requirements
Metabasis Therapeutics Announces First Quarter 2009 Financial Results
Metabasis Announces Conference Call and Live Webcast to Discuss First Quarter 2009 Financial Results
Metabasis Therapeutics Announces Late-Breaking Abstract on MB07803 Trial Results Accepted for Presentation at the American Diabetes Association Meeting
Metabasis Therapeutics Reports 2008 Fourth Quarter and Year End Financial Results
Metabasis Therapeutics Announces Positive Results in a Clinical Trial of MB07803 in Patients with Poorly Controlled Type 2 Diabetes
Metabasis Therapeutics Announces the Publication of Pre-Clinical Findings on MB07811, Its Product Candidate for the Treatment of Hyperlipidemia
Metabasis Therapeutics Appoints Tran B. Nguyen as Vice President and Chief Financial Officer
Metabasis Therapeutics to Present at the 11th Annual BIO CEO and Investor Conference
Metabasis Therapeutics Announces Corporate Restructuring and Workforce Reduction
Metabasis Therapeutics Announces Resignation of Dr. Paul Laikind and the Promotion of Dr. Mark Erion to Chief Executive Officer
Metabasis Therapeutics Announces Third Quarter 2008 Results and Recent Company Accomplishments and Announces Restructuring of Operations
Metabasis Therapeutics Reschedules Third Quarter 2008 Results and Conference Call
Results from Metabasis' Phase 2a Clinical Trial for MB07803 Show Statistically Significant Reductions in FPG, as Well as Safety and Tolerability
Metabasis to Present at Four Upcoming Healthcare Investor Conferences
Metabasis Announces Conference Call and Live Webcast to Discuss Third Quarter 2008 Financial Results
Metabasis Therapeutics Announces Initiation of a Clinical Trial for MB07803, Its Novel Product Candidate for the Treatment of Type 2 Diabetes
Metabasis Therapeutics Appoints Dr. Molly Holman as Vice President of Intellectual Property
Metabasis Therapeutics Announces Second Quarter 2008 Results and Comments on Recent Significant Company Accomplishments
Metabasis Therapeutics Announces Collaboration with Roche to Develop Liver-Targeted Compounds for the Treatment of Hepatitis C
Metabasis' Results from Its Phase 2a Clinical Trial for MB07803 to Be Presented at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension
Metabasis Announces Conference Call and Live Webcast to Discuss Second Quarter 2008 Financial Results
Metabasis to Present at the Collins Stewart 4th Annual Growth Conference
Metabasis Announces Promising Results from Its Phase 1b Clinical Trial for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia
Metabasis to Present at the Jefferies 2nd Annual Healthcare Conference
Metabasis Presents Preclinical Results for MB07803, Its Product Candidate for Type 2 Diabetes, and Its Glucagon Antagonist Program at the American Diabetes Association Meeting
Metabasis to Present at the American Diabetes Association Meeting and at the Canaccord Adams Diabetes & Obesity Conference
Metabasis to Present at the Bank of America 2008 Health Care Conference - Jun 2 2008 12:40AM
Metabasis Therapeutics Announces First Quarter 2008 Results and Recent Highlights - Jun 2 2008 12:40AM
Metabasis Therapeutics Announces Positive Results in the Phase 2a Clinical Trial for MB07803, Its Product Candidate for the Treatment of Type 2 Diabetes
Metabasis Therapeutics Announces Appointment of Dr. Elizabeth Stoner, Former Merck Clinical Development Executive, to Its Board of Directors
Metabasis Therapeutics Announces Extension of Its Collaboration with Merck & Co., Inc. to Develop AMPK Activators for Diabetes and Other Metabolic Diseases
Metabasis Therapeutics Raises Approximately $10 Million Through a Warrant Exchange and Concurrent Private Placement
Metabasis Announces Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results
Metabasis Therapeutics Presents the Discovery of Its Second-Generation FBPase Inhibitor, MB07803, at the 235th American Chemical Society National Meeting
Company Profile for Metabasis Therapeutics, Inc.